Henning Kelbæk

Showing 1-20 of 29 articles

Fractional flow reserve-guided PCI in patients with and without left ventricular hypertrophy: a DANAMI-3-PRIMULTI substudy

Sabbah M, Nepper-Christensen L, Lønborg J, Helqvist S, Køber L, Høfsten D, Ahtarovski K, Göransson C, Kyhl K, Schoos M, Vejlstrup N, Kelbæk H, Engstrøm T

September 18, 2020 | 10.4244/EIJ-D-19-00577

Coronary interventions

Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent: 3-Year Results of the TARGET All Comers Trial

Saito Y, Kelbæk H, Xu B, Hussain Y, Anderson R, Schächinger V, Zheng M, Wijns W, Baumbach A, Lansky A

June 2, 2020 | 10.4244/EIJ-D-20-00344

Myocardial damage after ST-segment elevation myocardial infarction by use of bivalirudin or heparin: a DANAMI-3 substudy

Schoos M, Nepper-Christensen L, Ahtarovski K, Kyhl K, Göransson C, Holmvang L, Kelbæk H, Helqvist S, Høfsten D, Køber L, Vejlstrup N, Lønborg J, Engstrøm T

April 3, 2020 | 10.4244/EIJ-D-19-00623

Coronary interventions

Five-year clinical outcomes for the Resolute zotarolimus-eluting stent in total coronary occlusions

Kelbæk H, Yeh R, Engstrøm T, Neumann F, Serruys P, Windecker S, Belardi J, Qiao S, Xu B, Liu M, Silber S

November 20, 2019 | 10.4244/EIJ-D-19-00866

Characterisation of lesions undergoing ischaemia-driven revascularisation after complete revascularisation versus culprit lesion only in patients with STEMI and multivessel disease: a DANAMI-3-PRIMULTI substudy

De Backer O, Lønborg J, Helqvist S, Warnøe J, Kløvgaard L, Holmvang L, Pedersen F, Tilsted H, Raungaard B, Jørgensen E, Køber L, Høfsten D, Kelbæk H, Engstrøm T

June 20, 2019 | 10.4244/EIJ-D-18-00766

Coronary interventions

Ten-year clinical outcome of patients treated with a drug-eluting stent in the proximal left anterior descending artery segment compared with patients stented in other non-left main coronary segments

Kjoller-Hansen L, Bligaard N, Kelbæk H, Christiansen E, Thuesen L, Hansen PR, Engstrøm T, Junker A, Abildgaard U, Lassen J, Jensen JS, Jeppesen JL, Galloe A

September 20, 2018 | 10.4244/EIJ-D-18-00396

STEMI

Impact of diagnostic ECG-to-wire delay in STEMI patients treated with primary PCI: a DANAMI-3 substudy

Nepper-Christensen L, Lønborg J, Hofsten D, Ahtarovski K, Kyhl K, Göransson C, Køber L, Helqvist S, Pedersen F, Kelbæk H, Vejlstrup N, Holmvang L, Engstrøm T

August 24, 2018 | 10.4244/EIJ-D-17-00857

Coronary interventions

To defer, or not to defer, that is the question

Kelbæk H, Hofsten D, Engstrøm T

July 20, 2017 | 10.4244/EIJV13I4A58

Coronary interventions

Bleeding episodes in “complete, staged” versus “culprit only” revascularisation in patients with multivessel disease and ST-segment elevation myocardial infarction: a DANAMI-3-PRIMULTI substudy

Sadjadieh G, Engstrøm T, Helqvist S, Hofsten D, Køber L, Pedersen F, Clemmensen P, Jørgensen E, Saunamäki K, Tilsted H, Kelbæk H, Holmvang L

November 20, 2016 | 10.4244/EIJV12I10A203

Coronary interventions

Acute myocardial infarction and lesion location in the left circumflex artery: importance of coronary artery dominance

Waziri H, Jørgensen E, Kelbæk H, Fosbøl E, Pedersen F, Mogensen U, Gerds T, Køber L, Wachtell K

July 20, 2016 | 10.4244/EIJY15M09_04

Coronary interventions

A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction

Kyhl K, Lønborg J, Vejlstrup N, Kelbæk H, Helqvist S, Holmvang L, Jørgensen E, Saunamäki K, Bøtker H, Clemmensen P, Køber L, Treiman M, Engstrøm T

July 20, 2016 | 10.4244/EIJV12I4A78

Coronary interventions

Long-term outcome of FFR-guided PCI for stable coronary artery disease in daily clinical practice: a propensity score-matched landmark analysis

De Backer O, Biasco L, Lønborg J, Pedersen F, Holmvang L, Kelbæk H, Arnous S, Saunamäki K, Helqvist S, Kastrup J, Jørgensen E, Engstrøm T

February 12, 2016 | 10.4244/EIJV11I11A247

Clinical results with the Resolute zotarolimus-eluting stent in total coronary occlusions

Kelbæk H, Holmvang L, Richardt G, Eberli F, Stella P, Buszman P, Neumann F, Serruys P, Windecker S, Widimsky P, Belardi J, Silber S

October 20, 2015 | 10.4244/EIJY14M07_14

Optimal catchment area and primary PCI centre volume revisited: a single-centre experience in transition from high-volume centre to “mega centre” for patients with ST-segment elevation myocardial infarction

Schoos M, Pedersen F, Holmvang L, Engstrøm T, Saunamäki K, Helqvist S, Kastrup J, Mehran R, Dangas G, Jørgensen E, Kelbæk H, Clemmensen P

September 22, 2015 | 10.4244/EIJY14M11_07

Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials

Taniwaki M, Stefanini G, Räber L, Brugaletta S, Cequier A, Heg D, Iñiguez A, Kelbæk H, Serra A, Ostojic M, Hernández-Antolín R, Baumbach A, Blochlinger S, Jüni P, Mainar V, Sabaté M, Windecker S

August 20, 2015 | 10.4244/EIJY14M07_12

How should I treat subacute stent thrombosis in the context of brain haemorrhage with abciximab?

Martin-Yuste V, Alvarez-Contreras L, Sabaté M, Kelbæk H, Saunamäki K, Jørgensen E, Kocka V

February 20, 2015 | 10.4244/EIJV10I10A208

ST peak during percutaneous coronary intervention serves as an early prognostic predictor in patients with ST-segment elevation myocardial infarction

Lønborg J, Kelbæk H, Engstrøm T, Helqvist S, Kløvgaard L, Holmvang L, Vejlstrup N, Jørgensen E, Saunamäki K, Dridi N, Kaltoft A, Bøtker H, Clemmensen P, Terkelsen C

August 19, 2014 | 10.4244/EIJV10I4A80

Flow disturbances in stent-related coronary evaginations: a computational fluid-dynamic simulation study

Radu M, Pfenniger A, Räber L, de Marchi S, Obrist D, Kelbæk H, Windecker S, Serruys P, Vogel R

May 20, 2014 | 10.4244/EIJV10I1A18

Natural history of optical coherence tomography-detected non-flow-limiting edge dissections following drug-eluting stent implantation

Radu M, Räber L, Heo J, Gogas B, Jørgensen E, Kelbæk H, Muramatsu T, Farooq V, Helqvist S, Garcia-Garcia H, Windecker S, Saunamäki K, Serruys P

January 20, 2014 | 10.4244/EIJV9I9A183

Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent

Meredith I, Verheye S, Weissman N, Barragan P, Scott D, Valdés Chávarri M, West N, Kelbæk H, Whitbourn R, Walters D, Kubica J, Thuesen L, Masotti M, Banning A, Sjogren I, Stables R, Allocco D, Dawkins K

July 26, 2013 | 10.4244/EIJV9I3A52

Latest news

NEW ISSUE

Infective Endocarditis & TAVI; Cerebral Protection Devices; IVUS Assessment in ViV-TAVI, Mini Focus on Antithrombotic Therapy …

February 19, 2021

NEW

Ahead of Print: OCT findings in ESR

Jincheng Guo et al.

February 24, 2021

Editorial

Consolidating the value of the standardised ARC-HBR definition

Giuseppe Gargiulo et al.

February 24, 2021

Trials Book

SCOPE 2, BASKET-SMALL 2 3 years, ALPHEUS, COMPARE-ABSORB, DUBIUS

(Thanks to the support of Biotronik)

January 13, 2021

Guidance Papers

Guidelines, consensus & position papers

August 28, 2020

JAA

This weeks JAA's: IVUS Guidewire Locations During Retrograde CTO, TF-TAVI endovascular closing and more..

February 16, 2021

NEW

European position paper on PFO – Part II

Christian Pristipino et al.